Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Marseille Cedex 5, France Clinical Trials

A listing of Marseille Cedex 5, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (555) clinical trials

Evaluation of Sentinel Node Policy in Early Stage Endometrial Carcinomas at Intermediate and High Risk of Recurrence.

Routine exams required for diagnosis: Endometrioid biopsy or product of a dilatation-curettage under hysteroscopy for diagnosis of histologic typing Tumor assessment: Lombopelvic MRI (1.5 or 3T) with gadolinium injection, studied by steady and dynamic sequences. US and CT-Scan in case of intolerance to MRI should be discussed. FDG-PET may be ...

Phase

0.0 miles

Learn More »

The SYMPTOMS - SYstematic Elderly Medical Patients Thromboprophylaxis: Efficacy on Symptomatic OutcoMeS - Study

Venous thromboembolism (VTE) is a frequent condition, affecting 1.8 per 1,000 people every year. Admission to hospital is one of the main risk factors for VTE, and could account for up to 20% of all VTE, making VTE prevention in admitted patients an appealing option to reduce VTE global burden. ...

Phase

0.0 miles

Learn More »

Efficacy Study on the Strategy of HSV-Tk Engineering Donor Lymphocytes to Treat Patients With High Risk Acute Leukemia

Delayed immune-reconstitution remains one of the main limitation of haploidentical stem cell transplantation. The risk of severe infections remains high for several months and CD3+ reconstitution could take more than 10 months. The low number of lymphocytes infused with the graft, the degree of HLA (Human Leukocyte Antigen) disparity, and ...

Phase

0.0 miles

Learn More »

Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer

This is a phase III study assessing 2 mutli-line therapeutic strategies in patients with unresectable wild-type RAS metastatic colorectal cancer. All the available treatments are being used in each strategy (oxaliplatine, irinotecan, fluoropyrimidines, bevacizumab, cetuximab or panitumumab) but in a different order: STRATEGY A: FOLFIRI-cetuximab, followed by oxaliplatin-based chemotherapy with ...

Phase

0.0 miles

Learn More »

Global Study of a Drug-coated Balloon to Treat Obstructive SFA and/or Popliteal Lesions

Cohort 1: Single-Arm, multicenter study to continue to assess the safety and performance of the Cardiovascular Ingenuity (CVI) Paclitaxel-Coated PTA Balloon Catheter in the treatment of de novo or restenotic lesions in the superficial femoral and/or popliteal arteries Cohort 2: To evaluate this patient population for treatment of in-stent restenotic ...

Phase N/A

0.0 miles

Learn More »

MOre REsponse on Cardiac Resynchronization Therapy With MultiPoint Pacing

This study is designed as a prospective, randomized, multi-center trial. Data will be collected at enrollment, baseline, implant procedure, patient classification, 6 months and 12 months of follow-up. During the 6-month visit, the patient's response to CRT will be evaluated according to LVESV reduction. Patients with an LVESV reduction of ...

Phase N/A

0.0 miles

Learn More »

Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders

OBJECTIVES: Primary - Evaluate the incidence of graft acceptance in patients with hematological disorders treated with combined immunosuppression before and after HLA-haploidentical hematopoietic stem cell transplantation. Secondary - Evaluate efficacy of this regimen in these patients. - Evaluate toxicity of this regimen in these patients. - Assess survival of patients ...

Phase

0.0 miles

Learn More »

A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine administered in combination with other anti-cancer therapies in a Genentech / Roche-sponsored parent study who are active and receiving benefit at the closure of parent study are eligible for continued treatment in this ...

Phase

0.0 miles

Learn More »

Bortezomib and Low Dose Cytarabine in the Treatment of High-Risk Myelodysplastic Syndromes

Four cycles of treatment are proposed at 28 day intervals in an ambulatory setting Cycle 1 : - Cytarabine 10 mg /m2/day subcutaneous injection for 14 days - Bortézomib 1,5mg/m2 days 1,4,8,11 Cycles 2, 3, 4 : - Cytarabine 20 mg /m2/j subcutaneous injections for 14 days - Bortézomib 1,5mg/m2 ...

Phase

0.0 miles

Learn More »

Lenalidomide in Subjects With intermediate2 or High MDS Associated With a Deletion (DEL) 5q [31]

Subjects meeting all inclusion and exclusion criteria will receive lenalidomide lenalidomide will be administered at 10 mg (two 5 mg capsules) once daily on Days 1–21, every 4 weeks. Bone marrow aspirate (baseline and during the course of the study at week 8, 16, 32, 52 and when clinically indicated/for ...

Phase

0.0 miles

Learn More »